178 related articles for article (PubMed ID: 24502962)
1. Lipoprotein (a), LPA Ile4399Met, and fibrin clot properties.
Rowland CM; Pullinger CR; Luke MM; Shiffman D; Green L; Movsesyan I; Devlin JJ; Malloy MJ; Kane JP; Undas A
Thromb Res; 2014 May; 133(5):863-7. PubMed ID: 24502962
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the I4399M variant of apolipoprotein(a): implications for altered prothrombotic properties of lipoprotein(a).
Scipione CA; McAiney JT; Simard DJ; Bazzi ZA; Gemin M; Romagnuolo R; Macrae FL; Ariëns RA; Hegele RA; Auld J; Gauld JW; Boffa MB; Koschinsky ML
J Thromb Haemost; 2017 Sep; 15(9):1834-1844. PubMed ID: 28632940
[TBL] [Abstract][Full Text] [Related]
3. Altered fibrin clot properties in patients on long-term haemodialysis: relation to cardiovascular mortality.
Undas A; Kolarz M; Kopeć G; Tracz W
Nephrol Dial Transplant; 2008 Jun; 23(6):2010-5. PubMed ID: 18156458
[TBL] [Abstract][Full Text] [Related]
4. High-density cholesterol and apolipoprotein AI as modifiers of plasma fibrin clot properties in apparently healthy individuals.
Ząbczyk M; Hońdo Ł; Krzek M; Undas A
Blood Coagul Fibrinolysis; 2013 Jan; 24(1):50-4. PubMed ID: 23037322
[TBL] [Abstract][Full Text] [Related]
5. Elevated lipoprotein(a) as a new risk factor of cerebral venous sinus thrombosis: association with fibrin clot properties.
Skuza AA; Polak M; Undas A
J Thromb Thrombolysis; 2019 Jan; 47(1):8-15. PubMed ID: 30511257
[TBL] [Abstract][Full Text] [Related]
6. Unfavorably Altered Fibrin Clot Properties in Patients with Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome): Association with Thrombin Generation and Eosinophilia.
Mastalerz L; Celińska-Lӧwenhoff M; Krawiec P; Batko B; Tłustochowicz W; Undas A
PLoS One; 2015; 10(11):e0142167. PubMed ID: 26540111
[TBL] [Abstract][Full Text] [Related]
7. Factor XIII Val34Leu polymorphism as a modulator of fibrin clot permeability and resistance to lysis in patients with severe coronary artery disease.
Stepień E; Plicner D; Kapelak B; Wypasek E; Sadowski J; Undas A
Kardiol Pol; 2009 Aug; 67(8A):947-55. PubMed ID: 19784898
[TBL] [Abstract][Full Text] [Related]
8. Fibrin clot properties are altered in patients with chronic obstructive pulmonary disease. Beneficial effects of simvastatin treatment.
Undas A; Kaczmarek P; Sladek K; Stepien E; Skucha W; Rzeszutko M; Gorkiewicz-Kot I; Tracz W
Thromb Haemost; 2009 Dec; 102(6):1176-82. PubMed ID: 19967149
[TBL] [Abstract][Full Text] [Related]
9. Plasma homocysteine affects fibrin clot permeability and resistance to lysis in human subjects.
Undas A; Brozek J; Jankowski M; Siudak Z; Szczeklik A; Jakubowski H
Arterioscler Thromb Vasc Biol; 2006 Jun; 26(6):1397-404. PubMed ID: 16574890
[TBL] [Abstract][Full Text] [Related]
10. Unfavorably altered fibrin clot properties in patients with active rheumatoid arthritis.
Kwasny-Krochin B; Gluszko P; Undas A
Thromb Res; 2010 Jul; 126(1):e11-6. PubMed ID: 20471669
[TBL] [Abstract][Full Text] [Related]
11. Increased plasma clot permeability and susceptibility to lysis are associated with heavy menstrual bleeding of unknown cause: a case-control study.
Szczepaniak P; Zabczyk M; Undas A
PLoS One; 2015; 10(4):e0125069. PubMed ID: 25909989
[TBL] [Abstract][Full Text] [Related]
12. Altered fibrin clot properties are associated with residual vein obstruction: effects of lipoprotein(a) and apolipoprotein(a) isoform.
Undas A; Cieśla-Dul M; Drążkiewicz T; Sadowski J
Thromb Res; 2012 Sep; 130(3):e184-7. PubMed ID: 22762941
[TBL] [Abstract][Full Text] [Related]
13. Plasma fibrin clot proteomics in healthy subjects: Relation to clot permeability and lysis time.
Ząbczyk M; Stachowicz A; Natorska J; Olszanecki R; Wiśniewski JR; Undas A
J Proteomics; 2019 Sep; 208():103487. PubMed ID: 31425886
[TBL] [Abstract][Full Text] [Related]
14. Thyroid dysfunction and fibrin network structure: a mechanism for increased thrombotic risk in hyperthyroid individuals.
Hooper JM; Stuijver DJ; Orme SM; van Zaane B; Hess K; Gerdes VE; Phoenix F; Rice P; Smith KA; Alzahrani SH; Standeven KF; Ajjan RA
J Clin Endocrinol Metab; 2012 May; 97(5):1463-73. PubMed ID: 22378816
[TBL] [Abstract][Full Text] [Related]
15. A new insight into retinal vein occlusion pathogenesis.
Karska-Basta I; Kubicka-Trzaska A; Pogrzebielski A; Romanowska-Dixon B
Klin Oczna; 2013; 115(4):269-74. PubMed ID: 24908915
[TBL] [Abstract][Full Text] [Related]
16. Abnormal plasma fibrin clot characteristics are associated with worse clinical outcome in patients with peripheral arterial disease and thromboangiitis obliterans.
Undas A; Nowakowski T; Cieśla-Dul M; Sadowski J
Atherosclerosis; 2011 Apr; 215(2):481-6. PubMed ID: 21324459
[TBL] [Abstract][Full Text] [Related]
17. Reduced plasma fibrin clot permeability and susceptibility to lysis in patients with inflammatory bowel disease: a novel prothrombotic mechanism.
Owczarek D; Cibor D; Sałapa K; Głowacki MK; Mach T; Undas A
Inflamm Bowel Dis; 2013 Nov; 19(12):2616-24. PubMed ID: 24108112
[TBL] [Abstract][Full Text] [Related]
18. Relationship of lipoprotein(a) to variables of coagulation in hypertensive subjects.
Sechi LA; De Marchi S
J Investig Med; 2001 Jan; 49(1):12-20. PubMed ID: 11217142
[TBL] [Abstract][Full Text] [Related]
19. Altered fibrin clot structure/function in patients with antiphospholipid syndrome: association with thrombotic manifestation.
Celińska-Lowenhoff M; Iwaniec T; Padjas A; Musiał J; Undas A
Thromb Haemost; 2014 Aug; 112(2):287-96. PubMed ID: 24652596
[TBL] [Abstract][Full Text] [Related]
20. Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: effects of inflammation and oxidative stress.
Undas A; Szułdrzynski K; Stepien E; Zalewski J; Godlewski J; Tracz W; Pasowicz M; Zmudka K
Atherosclerosis; 2008 Feb; 196(2):551-7. PubMed ID: 17640649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
